IMB Seminar Series - A/Professor Mark Smythe - Oral equivalents of antibody drugs: the pathway to an Au$119M Nasdaq listing
- Full Description:
- Protagonist Therapeutics is a 15-year “overnight success”, having recently undergone an oversubscribed Au$119M primary Nasdaq listing. In this presentation, I will outline the science and business evolution of the company from a technology-based start-up founded at The University of Queensland to what could be considered a global biotechnology company.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs). Our primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, our oral peptides offer targeted delivery to the diseased gastrointestinal (GI) tissue, the potential for improved safety due to minimal exposure in the blood and minimal systemic target blockade, improved convenience and compliance due to oral delivery. Our initial lead product candidates, PTG-100 and PTG-200, are orally delivered peptides with these advantages, and we believe they have the potential to transform the existing treatment paradigm for Inflammatory Bowel Disease and provide patients with significant longer term remission.
Directions to UQ
Share This Event
Rate This Event
Tweet This Event
Subscribe via RSS